Showing 1841-1850 of 2105 results for "".
- Promising Results from Study of Stem Cell Transplantation in People with Multiple Sclerosis Publishedhttps://practicalneurology.com/news/promising-results-from-study-of-stem-cell-transplantation-in-people-with-multiple-sclerosis-published/2470351/One-year results from a phase I clinical trial (NCT03282760) demonstrated the feasibility, safety, and tolerability of intracerebroventricular (ICV) human neural stem/progenitor cell (hNSC) transplantation in patients with secondary progressive multiple sclerosis (SPMS). Results were published in
- Breakthrough Device Designation Granted to Roche’s Elecsys Neurofilament Light Chain Test for Multiple Sclerosishttps://practicalneurology.com/news/breakthrough-device-designation-granted-to-roches-elecsys-neurofilament-light-chain-test-for-multiple-sclerosis/2470350/Roche’s Elecsys neurofilament light chain (NfL) test (Basel, Switzerland) received breakthrough device designation from the Food and Drug Administration (FDA). The test is intended to be used to detect disease activity in the serum and plasma of adults aged 18 to 55 years with relapsing-rem
- Recipients of the “Frontiers in Headache Research Scholarship Award” from the American Headache Society Announcedhttps://practicalneurology.com/news/recipients-of-the-frontiers-in-headache-research-scholarship-award-from-the-american-headache-society-announced/2470341/Ten recipients of the American Headache Society (AHS) Frontiers in Headache Research Scholarship Award have received complimentary meeting registration for the 2023 Scottsdale Headache Symposium, a travel stipend of up to $1000, and a full year of AHS Trainee membership. The AHS awards this schol
- FDA Grants Fast Track Designation to Investigational RNA Replacement Enzyme-Based Cancer Gene Therapy to Treat Glioblastomahttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-investigational-rna-replacement-enzyme-based-cancer-gene-therapy-to-treat-glioblastoma/2470336/RZ-001 (Rznomics; Yongin-si, South Korea), a candidate RNA replacement enzyme-based cancer gene therapy, has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for patients with glioblastoma (GBM). RZ-001 is designed to target
- Long-Term Data from Real-World CLARENCE Study Show Stable Disability Outcomes in Patients with Highly Active Relapsing MS Treated with Mavencladhttps://practicalneurology.com/news/long-term-data-from-real-world-clarence-study-show-stable-disability-outcomes-in-patients-with-highly-active-relapsing-ms-treated-with-mavenclad/2470330/After 5 years of follow-up, people with highly active relapsing multiple sclerosis (RMS) treated with Mavenclad (cladribine tablets; Merck, Darmstadt, Germany) showed high rates of treatment persistence and low rates of switching to other disease-modifying therapies (DMTs). These results from an
- Agamree Receives FDA Approval as First “Dissociative Steroidal Anti-Inflammatory” to Treat Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/agamree-receives-fda-approval-as-first-dissociative-steroidal-anti-inflammatory-to-treat-duchenne-muscular-dystrophy/2470327/Agamree (vamorolone; Catalyst Pharmaceuticals, Coral Gables, FL) has received Food and Drug Administration (FDA) approval as an oral suspension 40 mg/mL to treat Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. Agamree was developed by Santhera Pharmaceuticals (Pratteln, Swit
- Donanemab Treatment Effects in Early Stages of Alzheimer Disease Detailed in New Post-Hoc Analysis from TRAILBLAZER-ALZ 2https://practicalneurology.com/news/donanemab-treatment-effects-in-early-stages-of-alzheimer-disease-detailed-in-new-post-hoc-analysis-from-trailblazer-alz-2/2470324/According to post-hoc analyses of data from the TRAILBLAZER-ALZ 2 clinical trial (NCT04437511), people with baseline characteristics indicative of earlier stages of Alzheimer disease (AD), including lower tau PET, younger age, and plasma phosphorylated tau at threonine 217 (p-tau217) levels, show
- Dr. Anthony Lang Presents Novel SynNeurGe Model of Parkinson Disease Identificationhttps://practicalneurology.com/news/dr-anthony-lang-presents-novel-synneurge-model-of-parkinson-disease-identification/2470321/Dr. Anthony Lang, Professor of Neurology and Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, presented a new model for identifying Parkinson disease (PD) at the 26th World Congress of Neurology. The new model, SynNeurGe, is a framework consisting of 3 distinc
- Novel Monoclonal Antibody Which Targets Tau Protein Accumulation Receives IND Clearance from FDAhttps://practicalneurology.com/news/novel-monoclonal-antibody-which-targets-tau-protein-accumulation-receives-ind-clearance-from-fda/2470293/Oscotec (Seognam, South Korea) and ADEL (Seoul, South Korea) announced that their investigational new drug (IND) application for ADEL-Y01, a novel IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, was cleared by the Food and Drug Administration (FDA
- Is Infertility Treatment Associated with Stroke-Related Hospitalization?https://practicalneurology.com/news/is-infertility-treatment-associated-with-stroke-related-hospitalization/2470287/According to results of a study published in JAMA Network Open, infertility treatment is associated with an increased risk of hospitalization from hemorrhagic and ischemic stroke within 1 year of delivery. Patients receiving infertility treatment had an overall 66% increased risk of bein